Skip to content

Effect of thoracic paravertebral block combined with esketamine on anxiety and depression in patients undergoing thoracoscopic radical resection for lung cancer

Effect of thoracic paravertebral block combined with esketamine on anxiety and depression in patients undergoing thoracoscopic radical resection for lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099955
Enrollment
Unknown
Registered
2025-04-01
Start date
2025-04-15
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, anxiety, pain

Interventions

Esketamine group:Intravenous esketamine at the appropriate dose
Control group:None
Thoracic paravertebral block combined with esketamine group:The patient underwent a thoracic paravertebral block after induction of anesthesia, in addition to the corresponding dose of esketamine.

Sponsors

The First Hospital Of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.18 years old <= age <=75 years old, male or female; 2. Patients undergoing elective thoracoscopic radical resection of primary lung cancer under general anesthesia; 3.18kg/m2<=BMI<=32kg/m2; 4. American Society of Anesthesiologists (ASA) grade I-III; 5. Able to understand the use of pain scales, operate PCA equipment, and communicate effectively with researchers; 6. No contraindications to study drug use; 7. Clearly understand and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Severe cardiovascular system diseases, NYHA heart function grade 3~4; Heart block (sinus block or atrioventricular block); 2.Diseases of the kidney system (serum creatinine above the normal threshold); 3.Diseases of the liver system (Alt or Alt greater than twice the normal value); 4.Coagulation dysfunction (prothrombin time or activated partial thromboplastin time higher than the normal threshold); 5.Recently received antidepressant medication; 6.The drugs used in this study are contraindicated; 7.Alcohol abuse or heavy dependence on narcotic drugs in the last two months; 8.Recently received antidepressant medication; 9.Have severe mental or cognitive impairment; 10.Pregnant and lactating women; 11.With other primary cancer or malignancy.

Design outcomes

Primary

MeasureTime frame
Anxiety score;Depressive score;

Secondary

MeasureTime frame
Anxiety score;Intraoperative dosage of urapidil and ephedrine;Postoperative nausea, vomiting, dizziness, lethargy, pruritus, deep vein thrombosis, pulmonary embolism, atelectasis, intestinal obstruction, urinary retention, frequent urination and urgency;Postoperative pain score;The first time PCIA was used;Depressive score;Incidence of intraoperative hypertension, hypotension, bradycardia, dosage of urapidil and ephedrine.;Postoperative recovery quality;Sleep quality was assessed;

Countries

China

Contacts

Public ContactTang Li

The First Hospital Of Jiaxing

13456200070@qq.com+86 13456200070

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026